Nanobiotechnology and Nanomedicine Companies
Showing results 61 - 70 of 94 of companies in USA:
NanoHybrids develops nanoparticle contrast agents for Photoacoustics, Optical Imaging, Microscopy, Molecular Diagnostic and Theranostic applications.
NanoLight Technologies is a division of Prolume Ltd., a biotechnology company developing broad applications of natural, light-emitting marine proteins, or marine bioluminescence. The NanoLight division is focused on becoming the leader in high-value reagent & reporter systems for new product development in the pharmaceutical, agrichemical, and research products industries.
NanoMedical Systems (NMS) is a startup company, which will commercialize the patented research of Dr. Mauro Ferrari at the University of Texas Health Science Center in Houston, a sponsored research site and a source of licensed IP for NMS. The company's Personalized Molecular Drug-delivery System (PMDS) is a small drug delivery device that is implanted subcutaneously (just under the skin) for slow and consistent release of a therapeutic agent over many weeks or months. A nanochannel delivery system (nDS) embodied on a silicon chip regulates the flow of therapeutic molecules.
Develops and markets cellular imaging systems for the life sciences market.
Manufacturer of nanoparticle immunogold labeling and immunoassay tests.
Develops a therapeutic medical device which incorporates a new class of microparticles/nano-shells to selectively destroy solid tumors.
A nanotechnology-based platform for single molecule identification and digital quantification. The NanoString™ system uniquely barcodes individual target molecules, scans them, and delivers a literal inventory of target molecules in the biological sample.
Design, synthesis, and analysis of small molecule organic compounds for the pharmaceutical industry.
A nanobio-pharmaceutical company utilizing nanoscale materials and processes to develop anti-viral drugs against a wide range range of human and animal viruses.
Novavax is focused on creating novel, highly potent recombinant vaccines produced via cell culture. The company has developed three proprietary technology platforms: Virus-Like Particles, NovasomeŽ paucilamellar vesicles and Micellar Nanoparticles.